BSEColinz Laboratories Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 29 Apr, 2026 · 17:38 IST

FY26 Results: Revenue declines 6%, PAT up 3.6% YoY

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.6%Reaction day
₹47.84
prior close
₹47.84
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-3.3% vs market
Pharmaceuticals peers, median of 161sector-0.3%-3.3% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.6-0.4-3.3-0.3-3.3
Next day
+1.0+1.1-0.1+0.3+0.7
2d
+4.5+1.0+3.5+0.5+4.0
3d
-0.3+2.6-2.9+1.9-2.2
4d
+3.5+4.2-0.8+3.1+0.3
5d
+6.6+4.2+2.5+3.6+3.0
1w
+4.5-0.5+5.0+1.6+2.9
15d
-8.0+0.9-9.0+2.1-10.1
1m
+17.3+1.5+15.9+2.5+14.9
2m
+74.1+9.1+65.0+5.7+68.4
3m
+67.2+8.1+59.1+7.8+59.5
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Colinz Laboratories reported FY26 revenue from operations of Rs 613.61 lakhs, down 6% from Rs 652.77 lakhs in FY25. PAT rose to Rs 51.45 lakhs vs Rs 49.66 lakhs (+3.6%). Q4 FY26 showed strong recovery with revenue at Rs 174.79 lakhs (+20% YoY) and PAT at Rs 17.12 lakhs. Operating cash flow swung to positive Rs 254.11 lakhs from negative Rs 145.37 lakhs. Cash position strengthened to Rs 852.91 lakhs. Auditor issued unqualified opinion.

Likely market impact

Mixed results: full-year revenue declined, but profitability and cash flows improved. Q4 momentum is a positive signal.